<DOC>
	<DOCNO>NCT00004876</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Thalidomide may stop growth ovarian cancer stop blood flow tumor . PURPOSE : This randomized phase II trial study well give carboplatin together thalidomide work compare carboplatin alone treat patient ovarian epithelial cancer .</brief_summary>
	<brief_title>Carboplatin With Without Thalidomide Treating Patients With Ovarian Epithelial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety carboplatin thalidomide patient stage IC-IV ovarian cancer . - Determine antiangiogenic effect thalidomide patient population . - Compare efficacy carboplatin without thalidomide patient population . OUTLINE : This randomize study . Patients randomize one two treatment arm . - Arm I : Patients receive carboplatin IV 1 hour . Treatment continue every 4 week 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive carboplatin arm I . Patients receive thalidomide orally daily . Thalidomide treatment continue 24 week commence first day carboplatin therapy cease 4 week last course carboplatin . PROJECTED ACCRUAL : Approximately 30 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage ICIV ovarian epithelial cancer Postmenopausal OR Prior bilateral salpingooophorectomy and/or total abdominal hysterectomy PATIENT CHARACTERISTICS : Age : Over 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No concurrent invasive malignancy Not pregnant No diabetes mellitus No chronic neurological disease cause peripheral neuropathy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent cytotoxic agent Endocrine therapy : Not specify Radiotherapy : Concurrent local radiotherapy treatment secondary disease sit allow Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>stage IC ovarian epithelial cancer</keyword>
	<keyword>stage IIA ovarian epithelial cancer</keyword>
	<keyword>stage IIB ovarian epithelial cancer</keyword>
	<keyword>stage IIC ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
</DOC>